LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
Domaine:
healthcareType de record:
paper
Créateur:
LinHélAngDon
Éditeur:
Ben
Hôte:
Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq ® HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq ® sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq ® HIV-1 genotyping system for non-B subtypes HIV-1.
Similaires
Letter-to-the-Editor: Modelling the multi-functionality of African savanna landscapes under global changeLetter to the editor: Why we need to evaluate the quality of tuberculosis care in South Africa's private health sectorLetter to the editor: Clarifying the interpretation of declining adolescent pregnancy trends: implications for child protection and service provisionPerformance of the Cellslide<sup>®</sup> automated liquid-based cytology system amongst HIV-positive womenHIV-1 sequence data coverage in Central East Africa from 1959 to 2013The Status of HIV-1 Resistance to Antiretroviral drugs in Sub-Saharan Africa